Xenios and LEUKOCARE Announce Strategic Partnership in the Field of Anti-Inflammatory Coatings for Next Generation Extracorporeal Support Systems

Published: Oct 01, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MUNICH & HEILBRONN, Germany--(BUSINESS WIRE)--Xenios AG and LEUKOCARE AG, two German based life science companies, announced today a strategic alliance for the development and marketing of Xenios’ extracorporeal support systems with LEUKOCARE’s anti-inflammatory surface coating. LEUKOCARE has granted to Xenios a worldwide license of its relevant patents and know-how with exclusivity for anti-inflammatory surfaces. Moreover, Xenios has assigned LEUKOCARE with the adaptation of the clinically proven coating technology to Xenios’ broad range of medical devices that will be commercialized under Novalung, Medos and further Xenios brands.

Help employers find you! Check out all the jobs and post your resume.

Back to news